THC for Health & Longevity - Quick Reference Sheet
evipedia.ai
← Back

THC for Health & Longevity

Created on 09/22/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

THC is the intoxicating compound in cannabis, sold as a prescription oral medication and as regulated cannabis products, and used mainly for nausea, muscle stiffness and appetite loss. The strongest evidence is narrow: nausea during chemotherapy and muscle stiffness in multiple sclerosis. Pain and sleep findings point in opposite directions. No human research shows benefit in healthy adults, and the harms are better established than the benefits. (Full Review)

Protocol

Standard oral protocol
2.5 mg at night
Increased by 2.5 mg every 3–7 days to the lowest effective dose. Published clinical ranges run 2.5–30 mg daily; most non-cancer use settles at 5–10 mg.
Best time of day
Evening, 1–3 h before sleep
Applies to oral routes. Daytime dosing is confined to anti-nausea use around chemotherapy.
Age-related considerations
1 mg start over 65
Weekly rather than 3-day escalation, reflecting slower liver clearance, multiple concurrent medicines and reduced balance reserve.
Time to effect
Nausea and appetite
First dose
Anti-nausea and appetite effects appear with the first adequate dose.
Spasticity and pain
2–4 weeks
Titration period needed before response can be judged.
Sleep
Immediate
Sleep effects are immediate but may not persist.

Benefits

Contraindications
  • Personal or first-degree family history of schizophrenia, bipolar disorder with psychotic features, or any psychotic episode
  • Ischaemic heart disease, including recent myocardial infarction (<90 days), unstable angina, or heart failure (New York Heart Association Class III–IV)
  • History of arrhythmia, or resting heart rate above 100 beats per minute
  • Severe liver impairment (Child-Pugh Class C)
  • Current or prior cannabis use disorder, or active substance use disorder of any kind
  • Pregnancy, attempted conception, and lactation
  • Competitive athletes subject to in-competition testing
  • Anyone in a safety-sensitive occupation subject to workplace drug testing
    •
Key Interactions
  • Anticoagulants and antiplatelets (warfarin, phenprocoumon, clopidogrel)
  • Immunosuppressants (tacrolimus, sirolimus, cyclosporine)
  • Sedating drugs acting on the brain (benzodiazepines, opioids, gabapentinoids, sedating antihistamines)
  • Anticonvulsants (clobazam, valproate, phenytoin)
  • Over-the-counter agents (alcohol, sedating antihistamines such as diphenhydramine and doxylamine, grapefruit juice)
  • Supplement interactions (St John's wort, kava, valerian, cannabidiol)
  • Additive-effect supplements (melatonin, magnesium glycinate, glycine, ashwagandha, 5-HTP, beetroot nitrate, hibiscus)
  • Other intervention interactions (cognitive testing, heart-rate-variability measurement, exercise-based interventions)

Risk & Side Effects

  • High: Acute psychosis-like and anxiety symptoms; sedation, dizziness and impaired balance; acute cognitive impairment and crash risk; acute tachycardia and orthostatic hypotension
  • Medium: Cannabis use disorder; withdrawal syndrome on cessation; major adverse cardiovascular events; psychotic disorder with regular use of high-strength products
  • Low: Cannabinoid hyperemesis syndrome; persistent cognitive deficits with heavy use; chronic bronchitis from smoked routes; reduced semen quality
  • Speculative: Accelerated epigenetic aging; immunosuppression
    •

Monitoring

Marker Target Why
Resting heart rate 50–70 beats per minute, seated Detects the fast heart rate that tracks THC dose
Seated and standing blood pressure Under 120/80 mmHg seated; upper-number fall under 20 mmHg on standing Detects the standing blood-pressure drop behind THC-related falls
ALT 10–26 U/L in men, 8–22 U/L in women THC is cleared by the liver and often combined with other liver-cleared agents
GGT Under 20 U/L in men, under 15 U/L in women Earliest signal of added liver burden from combined substances
INR Within the prescribed individual target, usually 2.0–3.0 THC blocks the enzyme clearing warfarin, and bleeding events are documented
hs-CRP Under 1.0 mg/L Tests the claimed anti-inflammatory effect against an objective marker
HbA1c 4.8–5.3% Appetite stimulation can shift intake enough to move blood-sugar control
Total testosterone (men) 600–900 ng/dL Cannabis has been linked to altered reproductive hormones in some cohorts
CUDIT-R score Under 8 The dependence risk is the most probable long-term harm and is otherwise invisible
Cannabinoid signalling markers (anandamide, 2-arachidonoylglycerol) No established target range exists; change from the individual's own baseline Proposed mechanism for age-related benefit, but no clinical threshold has been validated

Cadence: Baseline before starting; blood pressure and heart rate at 1 week and 4 weeks after a stable dose is reached; liver enzymes and the dependence screen at 3 months; then everything reviewed every 6–12 months, or within 2 weeks of any dose increase.

Qualitative Assessment

  • Morning grogginess or a hangover-like feeling on the day after dosing
  • Sleep quality and dream recall, which change sharply during withdrawal
  • Cognitive clarity and word-finding during the 24 hours after a dose
  • Balance and confidence on stairs, particularly on dosing evenings
  • Anxiety or suspiciousness at the current dose compared with the previous one
  • Whether the intended symptom, rather than the drug effect, has actually improved
  • Any drift toward daily rather than intermittent use, or toward needing more for the same effect
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.